Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.

doi:10.1200/JCO.23.01225

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 May 2024

Lorusso Domenica, Raspagliesi Francesco, Ronzulli Dominique, Valabrega Giorgio, Colombo Nicoletta, Pisano Carmela, Cassani Chiara, Tognon Germana, Tamberi Stefano, Mangili Giorgia, Mammoliti Serafina, De Giorgi Ugo, Greco Filippo, Mosconi Anna Maria, Breda Enrico, Artioli Grazia, Andreetta Claudia, Casanova Claudia, Ceccherini Rita, Frassoldati Antonio, Salutari Vanda, Giolitto Serena, Scambia Giovanni

Abstract excerpt

PURPOSE: Literature evidence suggests that trabectedin monotherapy is effective in patients with recurrent ovarian cancer (OC) presenting BRCA mutation and/or BRCAness phenotype. METHODS: A prospective, open-label, randomized phase III MITO-23 trial evaluated the activity and safety of trabectedin 1.3 mg/m2 given once every 3 weeks (arm A) in BRCA 1/2 mutation carriers or patients with BRCAness phenotype (ie,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Alkylating

Share to Antineoplastic Combined Chemotherapy Protocols

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Share to Progression-Free Survival

Source

Open in PubMed

Identifiers

PMID: 38315944
DOI: 10.1200/JCO.23.01225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial.PMID 38315944Read ↗

Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trialSemantic proximity Read ↗

Ovarian cancer treatment in mutation carriers/BRCAness.Semantic proximity Read ↗

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)Semantic proximity Read ↗

Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?Semantic proximity Read ↗

Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge.Semantic proximity Read ↗

Trabectedin mechanism of action and platinum resistance: molecular rationale.Semantic proximity Read ↗

Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients.Semantic proximity Read ↗

Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.Semantic proximity Read ↗

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.Semantic proximity Read ↗

Trabectedin as a chemotherapy option for patients with BRCA deficiencySemantic proximity Read ↗

Platinum-Based Chemotherapy Versus Secondary Cytoreductive Surgery Before Olaparib Maintenance Therapy for 259 Patients with BRCA Mutated Platinum-Sensitive Recurrent Ovarian Cancer: A Multicenter Retrospective Study: Comparative Effectiveness and Survival Outcomes Analysis.Semantic proximity Read ↗

Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.